Pathophysiological link between diabetes and colorectal cancer:
effect of diabetic microenvironment, metformin and
5-fluorouracil on glyoxalase 1 protein level

a 2018

Pathophysiological link between diabetes and colorectal cancer: effect of diabetic microenvironment, metformin and 5-fluorouracil on glyoxalase 1 protein level

PÁCAL, Lukáš, Katarína CHALÁSOVÁ, Erik KROČKA, Alžbeta VISLOCKÁ, Kateřina KAŇKOVÁ et. al.

Basic information

Original name

Pathophysiological link between diabetes and colorectal cancer: effect of diabetic microenvironment, metformin and 5-fluorouracil on glyoxalase 1 protein level

Authors

PÁCAL, Lukáš, Katarína CHALÁSOVÁ, Erik KROČKA, Alžbeta VISLOCKÁ and Kateřina KAŇKOVÁ

Edition

13th International Symposium on the Maillard Reaction, 2018

Other information

Type of outcome

Konferenční abstrakt

Confidentiality degree

není předmětem státního či obchodního tajemství

Keywords (in Czech)

diabetes mellitus, kolorektální karcinom, metformin, glyoxaláza

Keywords in English

diabetes mellitus, colorectal cancer, metformin, glyoxalase

Abstract

V originále

Epidemiologic studies showed that (i) type 2 diabetes mellitus is associated with increased risk of certain cancers including colorectal cancer (CRC) and that (ii) CRC clinical outcome is worse in diabetics compared to non-diabetic subjects. On the other hand, antidiabetic treatment, specifically metformin, was associated with better prognosis and also increased efficacy of standard chemotherapeutic agents in CRC. Despite the indirect evidence of anticancer effects of metformin and sporadic evidence of its benefit as an adjuvant to standard chemotherapy mechanisms are not fully understood yet. One of links explaining adverse role of diabetes in cancer incidence and outcomes might involve increased dicarbonyl stress with subsequent up-regulation of glyoxalase 1 (GLO1). While increased GLO1 level or activity in diabetic patients may be beneficial, in some tumors, including CRC, a higher level of GLO1 may confer invasive, metastatic potential and diminish tumor sensitivity to therapy. So far it is unclear whether metformin might play a direct role in regulating cancer sensitivity to therapy and whether GLO1 might mediate such effects. Aim of the project was to study the effect of (i) diabetic microenvironment, (ii) metformin and (iii) first line CRC cytostatic agent 5-fluorouracil (5-FU) on GLO1 protein level in two colorectal cancer cell lines in vitro.

Links

GA16-14829S, research and development project

Name: Efekt diabetického mikroprostředí na vybrané procesy při vzniku kolorektálního karcinomu, jeho klinický průběh a odpověď na terapii

Investor: Czech Science Foundation

Citovat

PÁCAL, Lukáš, Katarína CHALÁSOVÁ, Erik KROČKA, Alžbeta VISLOCKÁ and Kateřina KAŇKOVÁ. Pathophysiological link between diabetes and colorectal cancer: effect of diabetic microenvironment, metformin and 5-fluorouracil on glyoxalase 1 protein level. In 13th International Symposium on the Maillard Reaction. 2018.

@proceedings{1436516,
   author = {Pácal, Lukáš and Chalásová, Katarína and Kročka, Erik and Vislocká, Alžbeta and Kaňková, Kateřina},
   booktitle = {13th International Symposium on the Maillard Reaction},
   keywords = {diabetes mellitus, colorectal cancer, metformin, glyoxalase},
   title = {Pathophysiological link between diabetes and colorectal cancer: effect of diabetic microenvironment, metformin and 5-fluorouracil on glyoxalase 1 protein level},
   year = {2018}
}

TY  - CONF
ID  - 1436516
AU  - Pácal, Lukáš - Chalásová, Katarína - Kročka, Erik - Vislocká, Alžbeta - Kaňková, Kateřina
PY  - 2018
TI  - Pathophysiological link between diabetes and colorectal cancer: effect of diabetic microenvironment, metformin and 5-fluorouracil on glyoxalase 1 protein level
KW  - diabetes mellitus, colorectal cancer, metformin, glyoxalase
N2  - Epidemiologic studies showed that (i) type 2 diabetes mellitus is associated with increased risk of certain cancers including colorectal cancer (CRC) and that (ii) CRC clinical outcome is worse in diabetics compared to non-diabetic subjects. On the other hand, antidiabetic treatment, specifically metformin, was associated with better prognosis and also increased efficacy of standard chemotherapeutic agents in CRC. Despite the indirect evidence of anticancer effects of metformin and sporadic evidence of its benefit as an adjuvant to standard chemotherapy mechanisms are not fully understood yet. One of links explaining adverse role of diabetes in cancer incidence and outcomes might involve increased dicarbonyl stress with subsequent up-regulation of glyoxalase 1 (GLO1). While increased GLO1 level or activity in diabetic patients may be beneficial, in some tumors, including CRC, a higher level of GLO1 may confer invasive, metastatic potential and diminish tumor sensitivity to therapy. So far it is unclear whether metformin might play a direct role in regulating cancer sensitivity to therapy and whether GLO1 might mediate such effects. Aim of the project was to study the effect of (i) diabetic microenvironment, (ii) metformin and (iii) first line CRC cytostatic agent 5-fluorouracil (5-FU) on GLO1 protein level in two colorectal cancer cell lines in vitro.
ER  -

PÁCAL, Lukáš, Katarína CHALÁSOVÁ, Erik KROČKA, Alžbeta VISLOCKÁ and Kateřina KAŇKOVÁ. Pathophysiological link between diabetes and colorectal cancer: effect of diabetic microenvironment, metformin and 5-fluorouracil on glyoxalase 1 protein level. In \textit{13th International Symposium on the Maillard Reaction}. 2018.

Detailed Information on Publication Record